NCT01553851View on ClinicalTrials.gov

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Neoplasms, OralMouth Neoplasms
Interventions
DRUG

GSK1120212

Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Washington University School of Medicine

OTHER

NCT01553851 - GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | Biotech Hunter | Biotech Hunter